Andrea F. Wainer - 15 Nov 2021 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Andrea F. Wainer by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
15 Nov 2021
Net transactions value
-$1,102,111
Form type
4
Filing time
17 Nov 2021, 17:18:00 UTC
Previous filing
03 Sep 2021
Next filing
08 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $235,000 +5,000 +10% $47.00 54,782 15 Nov 2021 Direct
transaction ABT Common shares without par value Options Exercise $288,000 +7,500 +14% $38.40 62,282 15 Nov 2021 Direct
transaction ABT Common shares without par value Sale $1,625,111 -12,500 -20% $130.01 49,782 15 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -5,000 -13% $0.000000 33,226 15 Nov 2021 Common Shares 5,000 $47.00 Direct F2
transaction ABT Option (right to buy) Options Exercise $0 -7,500 -25% $0.000000 22,500 15 Nov 2021 Common Shares 7,500 $38.40 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $130.00 to $130.03, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).